GlaxoSmithKline plc 6.7% Potential Decrease Indicated by Barclays Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘EQUAL WEIGHT’ today by analysts at Barclays Capital. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 1650 GBX on its stock. This would imply the analyst believes there is a potential downside of -6.7% from the opening price of 1768.8 GBX. Over the last 30 and 90 trading days the company share price has increased 98.8 points and increased 96 points respectively. The 52 week high for the stock is 1796.4 GBX while the 52 week low for the share price is 1408.8 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,705.66 GBX and the 200 Day Moving Average price is recorded at 1,616.95. There are currently 4,988,724,301 shares in issue with the average daily volume traded being 10,002,460. Market capitalisation for LON:GSK is £87,901,322,183 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search